RT Journal Article
T1 Impact of prior antihypertensive treatment on COVID-19 outcomes, by active ingredient
A1 García-Álvarez, Rosa María
A1 Zapata Cachafeiro, Maruxa
A1 Visos‐Varela, Irene
A1 Rodríguez Fernández, Almudena
A1 Pintos‐Rodríguez, Samuel
A1 Piñeiro Lamas, María
A1 Herdeiro, Maria Teresa Ferreira
A1 Figueiras Guzmán, Adolfo
A1 Salgado Barreira, Ángel
A1 COVID-Drug Group, 
A1 Bugarín‐González, Rosendo
A1 Carracedo Martínez, Eduardo
A1 González Barcala, Francisco Javier
A1 Lema Oreiro, Martina
A1 Mallah, Narmeen
A1 Portela Romero, Manuel
A1 Prieto Campo, Ángela
A1 Saez, Marc
A1 Taracido Trunk, Margarita
K1 Enalapril
K1 Candesartan
K1 Mortality
K1 Hospitalization
K1 COVID-19
AB ObjectivesTo assess the impact of prior chronic treatment with angiotensin-converting enzyme inhibitors (ACEIs)/ angiotensin-receptor blockers (ARBs), both as a group and by active ingredient, on severity (risk of hospitalization and mortality), progression of and susceptibility to COVID-19.MethodsWe conducted a multiple population-based case–control study in Galicia (north-west Spain). The study data were sourced from medical, administrative and clinical databases. We assessed: (1) risk of hospitalization, by selecting all patients hospitalized due to COVID-19 with PCR + as cases, and a random sample of subjects without a PCR + as controls; (2) COVID-19 mortality risk; (3) risk of disease progression; and (4) susceptibility to SARS-CoV-2, considering all patients with PCR + as cases, and the same subjects used in the previous model as controls. Adjusted odds ratios (aORs) were calculated.ResultsACEIs and ARBs were shown to decrease the risk of hospitalization (aOR = 0.78 [95%CI 0.69–0.89] and aOR = 0.80 [95%CI 0.72–0.90] respectively), risk of mortality (aOR = 0.71 [95%CI 0.52–0.98] and aOR = 0.69 [95%CI 0.52–0.91] respectively), and susceptibility to the virus (aOR = 0.88 [95%CI 0.82–0.94] and aOR = 0.92 [95%CI 0.86–0.97] respectively). By active ingredient: use of enalapril was associated with a significantly lower risk of hospitalization (aOR = 0.72 [95%CI 0.61–0.85]), mortality (aOR = 0.59 [95%CI 0.38–0.92]) and susceptibility to COVID-19 (aOR = 0.86 [95%CI 0.79–0.94]); and use of candesartan was associated with a decreased risk of hospitalization (aOR = 0.76 [95%CI 0.60–0.95]), mortality (aOR = 0.36 [95%CI 0.17–0.75]) and disease progression (aOR = 0.73 [95%CI 0.56–0.95]).ConclusionThis large-scale real-world data study suggest that enalapril and candesartan are associated with a considerable reduction in risk of severe COVID19 outcomes.
PB Springer
SN 0925-4692
YR 2024
FD 2024
LK http://hdl.handle.net/10347/34760
UL http://hdl.handle.net/10347/34760
LA eng
NO García-Álvarez, R.M., Zapata-Cachafeiro, M., Visos-Varela, I. et al. Impact of prior antihypertensive treatment on COVID-19 outcomes, by active ingredient. Inflammopharmacol 32, 1805–1815 (2024). https://doi.org/10.1007/s10787-024-01475-2
NO This study was sponsored by the Carlos III Institute of Health via the “COV20/00470” project (co-funded by the European Regional Development Fund, “A way to make Europe”).
DS Minerva
RD 28 abr 2026